ReviewPharmacoEconomics2001
Pharmacoeconomics of hypertension management: the place of combination therapy.
Review in PharmacoEconomics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.Cardiovascular diabetology · 2009Pooled it
- Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension.The Canadian journal of cardiology · 2007Trial
- [Effectiveness of combined therapy at set doses in a cohort of hypertense patients not controlled by single therapy].Atencion primaria · 2003Trial
- Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.Journal of clinical hypertension (Greenwich, Conn.)Trial
- Article
- Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation(®) Program: A Research Review Update.Current hypertension reviews · 2012Article
- The managed hypertensive: the costs of blood pressure control in a Nigerian town.The Pan African medical journal · 2012Article
- Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.Core evidence · 2010Article
- The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.International journal of clinical practice · 2008Review
- Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.Vascular health and risk management · 2007Review
- Clinical and Pre-clinical Applications of the Transcendental Meditation Program in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults.Current hypertension reviews · 2006Article
- Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study.Journal of human hypertension · 2005Article
- Fixed low-dose combination therapy for hypertension.Current hypertension reports · 2002Review
- Cost-effectiveness of hypertension treatment: a population-based study.Sao Paulo medical journal = Revista paulista de medicina · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological treatment of hypertension has been shown to reduce the risk of stroke, coronary events, heart failure and progression of renal disease. However, rates of successful blood pressure control remain low among treated patients while antihypertensive medication represents a large and increasing proportion of healthcare expenditure in many countries. Several influential pharmacoeconomic analyses have confirmed the cost effectiveness of conventional antihypertensive treatments, usually involving monotherapy with diuretics or beta-blockers, compared with alternative strategies. Recent research has shown that a considerable proportion of the total cost of antihypertensive treatment in general practice is due to factors such as inadequate blood pressure control, poor compliance with therapy, discontinuation and switching between therapies. These factors operate to a much lesser extent in well-conducted clinical trials, and have not been fully incorporated into most economic studies. Some novel strategies, particularly low dose combinations of antihypertensive agents, may offer advantages in terms of efficacy, reduced adverse effects and improved compliance with treatment. There is therefore a need for comprehensive pharmacoeconomic analyses of novel strategies, taking these additional factors into account. Until such studies are available, the wider use of low dose combination therapy and other novel strategies should not be held back on the basis of earlier economic studies that have not included all relevant considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.